文摘
SMARCA4 and SMARCA2 deficiency is observed in 10% of consecutive NSCLC cases. In contrast to SWI/SNF-deficient carcinomas from other organs, differentiated (glandular or squamous) histology is frequent in SWI/SNF-deficient pulmonary carcinomas. SMARCA4 and SMARCA2 should be included in the workup of TTF1-negative adenocarcinoma of presumable pulmonary origin as 80% of SMARCA4/SMARCA2-deficient lung adenocarcinomas are TTF1 negative. Given the recently reported potential role of SMARCA4 loss as a predictor of chemosensitivity to platinum-based chemotherapy in resected NSCLC, recognition of SMARCA4-deficient NSCLC in routine surgical pathology practice is recommended.